Genes into Profits?

Merck's acquisition of genomics pioneer Rosetta Inpharmatics may give the No. 2 drug company a huge advantage in developing new drugs

/bwdaily/dnflash/jun2001/nf20010621_887.htm

Before it's here, it's on the Bloomberg Terminal. LEARN MORE